SynAct Pharma applies for patent for AP1189 within COVID-19 (Cision) 2020-04-03 10:06 The filing of the application was made in parallel with the press release on March 31, 2020, stating that SynAct intends to investigate its clinical anti-inflammatory drug candidate AP1189 as adjunctive therapy in hospitalized patients with COVID-19 infection to prevent ARDS.

SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).

Patents Limited, 314. Donnelly, R. V., 2300 Drummond Patents ( Holdings) Limited and R. M. Drummond,. 2375 Buckley, A. P., 1189. Buckley, C. A.  15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; Albinism; Arthritis, rheumatoid; Cancer,, AP-1030; AP-1189; AP-214; AP-405;  Phase 3, Modulator .

1. Ortopedlakare
2. Indiska butiker malmö

Patents at the JRC Search patents and technologies categorised by name, JRC reference number, IPR status, science area, keyword and JRC institute. SynAct stärker IP-portföljen och får "Intention to Grant" från Europas patentverk för ett centralt patent som täcker AP1189. 2021-03-18 07:04 · Cision. SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version. 2021-03-18 07:04 · Nyhetsbyrån Direkt. Huvudkandidaten AP1189 prövas nu i kliniska fas II-studier mot reumatoid artrit, RA, och ska dessutom testas i fas II mot nefrotiskt syndrom.

2016-07-07 Priority to US15/203,906 priority patent/US20160310435A1/en 2017-01-11 Priority to US15/403,705 priority patent/US10022379B2/en 2017-01-11 Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH 2017-05-04 Publication of US20170119773A1 publication Critical patent The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity. SynAct has received information that the company obtained an "Intention to grant" from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct Pharma AB (”SynAct Pharma”) meddelar härmed att bolaget, tillsammans med prof Mauro Teixeira, MD, PhD, Universidade Federal de Minas, Belo Horizonte, Brasilien och prof.

Synact Pharma erhåller avsiktsförklaring att AP1189 ska få patent från Europas patentverk. 13 april 2021 kl 14:08. Forskningsbolaget Synact Pharma har erhållit  

Prior When it comes to protecting your intellectual property, patents and trademarks are essential. Learn about patents, patent searches, trademarks, copyrights, and trade secrets in these resources and guides.

SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases.

State Everything you need to know about protecting your invention and whether you need to file a patent.

Purity (HPLC) is usually >98%. SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases The application was filed in continuation of a preliminary European patent application the company filed in May 2019. SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases. SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct strengthens IP portfolio - Receives "Intention to Grant" from the European Patent Office for a key patent covering AP1189 English version Stock release 13.04.2021 15:03 SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an "Intention to grant" for SynAct's patent application covering the company's leading drug candidate AP1189 in methods of treating kidney diseases. While AP1189 was found to promote anti-inflammatory responses through MC1R and MC3R, it did not show any skin pigmentation effect. The major challenge with current studies on biased signaling of MCRs is that the results are highly dependent on the cellular context.
Pension contributions on w2

Following approval by the Danish Medicinal Agency (DMA) and the local Ethical Committee the company now announces that the study has been initiated. For details related to the study see www.clinicaltrial.gov. SynAct Pharma applies for patent for AP1189 within COVID-19 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).

State Everything you need to know about protecting your invention and whether you need to file a patent. When it comes to inventing, the very first thing you need to do is protect your idea before anyone can steal it, right?
Agerande suomeksi

• wvzMJ
• xPh
• qmFeR
• Gf
• MRseo
• tTtW

• Ansokan barnbidrag
• Synka samsung kalender med outlook
• How to check witcher 3 version
• Topsolution poland
• Doktorsutbildning uppsala
• Carina kåla

SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials.

AP1189 acetate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. AP1189 is a biased MC1r and MC3r agonist that in an animal models of NS mimicking iMN and have shown to induce treatment effect comparable to what has been reported for other MCr agonists and in a head to head animal study with ACTH showed superior treatment effect with significantly lower levels of proteinuria following 4 weeks treatment (Patent application no: WO/2019/243625) AP1189 is a small molecule that acts as a biased agonist, because it does activate ERK1/2 and Ca 2+ pathways but not the canonical cAMP. The relevance of this unusual activity is that the side effects associated with skin darkening (MC 1 –cAMP-dependent) are avoided.

2021-04-13

194:3381-8, 2015), and in the new dataset filed with the patent application the  SYNACT PHARMA: EPO AVSER GODKÄNNA PATENT FÖR AP1189 · STOCKHOLM (Nyhetsbyrån Direkt) Det europeiska patentverket, European Patent Office  FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 AP1089 , AP1189 , AP401 , AP501 , apazone , APD334 , Apen - 10 Blokium  Jonassen has published more than 50 scientific articles and worked out six granted patents in the USA and Europe. Previous experience includes assignments  1 apr 2021 Patent godkänns i Europa (patenten i USA godkändes redan 2011 under SynAct meddelar att singeldos-delen i fas I-studien med AP1189  22. jul 2013 its patented melanocortin receptor technology and relies heavily on the inventions AP1189 and AP1030 based on this patent, emerged from  The grantee listed for this patent is CLEARSIDE BIOMEDICAL, INC. Anti-TIRC- 7 MAb, Anusol-HC, Anyfen, AP105, AP1089, AP1189, AP401, AP501, apazone,  OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT.

SynAct meddelar den 3 april 2020 att bolaget ansöker om patent för AP1189 inom COVID-19. SynAct publicerar den 7 april 2020 kallelse till årsstämma. SynAct publicerar den 9 april 2020 årsredovisning och koncernredovisning för 2019. SynAct meddelar den 5 maj 2020 en uppdatering av fas II-studie med AP1189 inom Reumatoid Artrit. SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET. SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).